

<p>Name of Policy: <u>Use of Hepatitis B Immune Globulin for Employees Exposed to Hepatitis B</u></p> <p>Policy Number: 3364-109-EH-502</p> <p>Department: Infection Control Hospital Administration Medical Staff</p> <p>Approving Officer: Chair, Infection Control Committee Chief of Staff Chief Medical Officer</p> <p>Responsible Agent: Infection Preventionist</p> <p>Scope: The University of Toledo Medical Center and its Medical Staff</p>	 <p>Effective Date 09/01/2023 Initial Effective Date: 11/9/77</p>
<p> <input type="checkbox"/> New policy proposal <input type="checkbox"/> Minor/technical revision of existing policy <input type="checkbox"/> Major revision of existing policy <input checked="" type="checkbox"/> Reaffirmation of existing policy </p>	

(A) Policy Statement

Hepatitis B immune globulin (HBIG) will be used to protect healthcare professionals who are occupationally exposed to hepatitis B virus (HBV), who lack documentation of vaccination, who are unvaccinated or who had an incomplete vaccinate series.

(B) Purpose of Policy

Hepatitis B immune globulin (HBIG) provides passive immunity or antibodies to HBV infection (anti-HBs) and temporary (i.e., 3–6 months) protection to persons exposed to the hepatitis B virus (HBV). This policy outlines HBIG use.

NOTE: Passively acquired anti-HBs can be detected for 4-6 months after administration of HBIG.

(C) Procedure

- (1) In order to effectively monitor usage of HBIG, all employee exposures to HBV must report immediately to the Emergency Department for evaluation and management.
- (2) The indications for use of HBIG are following the DIRECT exposure to HBV as demonstrated by a positive test for hepatitis B surface antigen (HBsAg). Direct occupational exposure includes contact with blood or body fluids via:
 - (a) Parenteral exposure (needlestick, bite, sharps)
 - (b) Direct mucous membrane contact
 - (c) Oral ingestion
- (3) Prior to administration of HBIG, and if the employee has not completed the HBV vaccine series, obtain serum from the exposed employee for HBsAg, hepatitis B core antibody (anti-HBc), and hepatitis B surface antibody (anti-HBs).
- (4) Do not give Hepatitis B Immune Globulin if the employee is:
 - (a) HBsAg-positive

- (b) Completed HBV vaccine series with documented immunity (anti-HBs \geq 10 mIU/ml)
- (5) Administer HBIG and initiate the HBV vaccine series:
 - (a) If the source patient is HBsAg-positive or the source patient is unknown
 - (b) The employee is not previously vaccinated, incompletely vaccinated, or known to have lack of immunity after completed HBV series
- (6) If indicated, the recommended dose of HBIG is 0.06 mL/kg of body weight in adults. After results of the patient/employee are known, the appropriate dose should be administered intramuscularly as soon as possible, preferably within 24 hours after exposure.
- (7) Prior to administering, provide the employee with side effects according to package insert.
- (8) Live virus vaccines should not be given close to the time of HBIG administration.

References

Center for Disease Control and Prevention. (2013). *CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management*. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6210a1.htm>

Center for Disease Control and Prevention. (2018). *Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices*. Retrieved from <https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm>

<p>Approved by:</p> <p>/s/ _____ 08/28/2023 Michael Ellis, M.D. Chair, Infection Control Committee Date</p> <p>/s/ _____ 08/30/2023 Asif Mahmood, MD Chief of Staff Date</p> <p>/s/ _____ 08/28/2023 Michael Ellis, M.D. Chief Medical Officer Date</p> <p><i>Review/Revision Completed By: Infection Control Committee</i></p>	<p>Review/Revision Date:</p> <p>10/20/77 10/15/2001 12/78 10/18/2004 2/14/79 11/26/2007 4/21/80 05/23/2011 1/19/81 07/14/2014 12/21/81 06/30/2017 4/19/82 08/11/2020 6/20/83 08/22/2023 7/25/83 10/84 11/84 9/13/85 5/18/87 5/9/88 8/7/89 8/6/90 4/8/92 3/8/95 6/1/98</p> <hr/> <p>Next Review Date: 08/2026</p>
<p>Policies Superseded by This Policy:</p>	